Cargando…
The ESMO position paper on biosimilars in oncology: enhancing the provision of accurate education and information
Autores principales: | Schiestl, Martin, Krendyukov, Andriy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5640113/ https://www.ncbi.nlm.nih.gov/pubmed/29071126 http://dx.doi.org/10.1136/esmoopen-2017-000245 |
Ejemplares similares
-
Extrapolation concept at work with biosimilar: a decade of experience in oncology
por: Krendyukov, Andriy, et al.
Publicado: (2018) -
Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained
por: Aapro, Matti, et al.
Publicado: (2018) -
Early Access Provision for Innovative Medicinal Products in Oncology: Challenges and Opportunities
por: Krendyukov, Andriy
Publicado: (2020) -
Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?
por: Goldsmith, David, et al.
Publicado: (2018) -
Early access provision: Awareness, educational needs and opportunities to improve oncology patients’ access to care
por: Krendyukov, Andriy, et al.
Publicado: (2022)